EGX-A is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a full agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and produces antidepressant-like effects in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of January 2024, it is in the preclinical research stage of development.
See also List of investigational hallucinogens and entactogens List of investigational antidepressants
References
External links Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin - atai Life Sciences (November 21, 2023) - LinkedIn